Michael Bullano (M Bullano)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 16

Top Topics

Atrial Fibrillation

Smoking Cessation

Cross Sectional

Top Venues

Expert review of pharmacoeconomics & outcomes research

Journal of medical economics

Haemophilia : the official journal of the World Federation of Hemophilia

Expert review of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Shan Xing, Michael Bullano, Sarah A Hale, Tasneem Lokhandwala, Kathryn DeYoung, Sharanya Murty
Longitudinal characterization of symptoms, healthcare resource utilization, and costs among people with thrombotic thrombocytopenic purpura compared with non-thrombotic thrombocytopenic purpura controls. Journal of medical economics 27 (1) (2024)
Shan Xing, Michael Bullano, Sarah A Hale, Tasneem Lokhandwala, Kathryn DeYoung, Sharanya Murty
Longitudinal characterization of symptoms, healthcare resource utilization, and costs among people with thrombotic thrombocytopenic purpura compared with non-thrombotic thrombocytopenic purpura controls. Journal of medical economics (2024)
Michael Bullano, Christina Cool, Bob G Schultz, Sneha Durgapal, Naomi C Sacks, Yanmei Liu, Rebecca Kee, Katharine Batt
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert review of pharmacoeconomics & outcomes research (2023)
Katharine Batt, Shan Xing, Maja Kuharic, Michael Bullano, Jorge Caicedo, Sreya Chakladar, Riddhi Markan, Sepehr Farahbakhshian
Real-world analysis of patients with haemophilia A and haemophilia A carriers in the United States: Demographics, clinical characteristics and costs. Haemophilia : the official journal of the World Federation of Hemophilia 29 (3) (2023)
Michael Bullano, Christina Cool, Bob G Schultz, Sneha Durgapal, Naomi C Sacks, Yanmei Liu, Rebecca Kee, Katharine Batt
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert review of pharmacoeconomics & outcomes research 23 (2) (2023)
Sepehr Farahbakhshian, Timothy J Inocencio, Gregory Poorman, Ekaterina Wright, Ravi Ramesh Pathak, Michael Bullano
Re: Response letter to Sanofi's communication related to "the budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States". Journal of medical economics 26 (1) (2023)
Katharine Batt, Shan Xing, Maja Kuharic, Michael Bullano, Jorge Caicedo, Sreya Chakladar, Riddhi Markan, Sepehr Farahbakhshian
Real-world analysis of patients with haemophilia A and haemophilia A carriers in the United States: Demographics, clinical characteristics and costs. Haemophilia : the official journal of the World Federation of Hemophilia (2023)
Michael Bullano, Christina Cool, Bob G Schultz, Sneha Durgapal, Naomi C Sacks, Yanmei Liu, Rebecca Kee, Katharine Batt
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert review of pharmacoeconomics & outcomes research 23 (2) (2023)
Katharine Batt, Shan Xing, Maja Kuharic, Michael Bullano, Jorge Caicedo, Sreya Chakladar, Riddhi Markan, Sepehr Farahbakhshian
Real-world analysis of patients with haemophilia A and haemophilia A carriers in the United States: Demographics, clinical characteristics and costs. Haemophilia : the official journal of the World Federation of Hemophilia 29 (3) (2023)
Miguel A Escobar, Neha Agrawal, Sagnik Chatterjee, Swastik Bhattacharya, Jorge Caicedo, Michael Bullano, Bob G Schultz
Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors. Journal of medical economics (2023)
Miguel A Escobar, Michael Bullano, Ali G Mokdad, Jorge Caicedo, Bob G Schultz, Qi Fan, Sumit Verma
A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors. Expert review of hematology (2023)
Nathan T Connell, Jorge Caicedo, N Nieto, Sagnik Chatterjee, A Hait, A K Gupta, Michael Bullano, Bob G Schultz
Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia. Expert review of pharmacoeconomics & outcomes research (2023)
Michael Bullano, Christina Cool, Bob G Schultz, Sneha Durgapal, Naomi C Sacks, Yanmei Liu, Rebecca Kee, Katharine Batt
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert review of pharmacoeconomics & outcomes research 23 (2) (2023)
Sepehr Farahbakhshian, Timothy J Inocencio, Gregory Poorman, Ekaterina Wright, Ravi Ramesh Pathak, Michael Bullano
The budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States. Journal of medical economics 25 (1) (2022)
Michael Bullano, Christina Cool, Bob G Schultz, Sneha Durgapal, Naomi C Sacks, Yanmei Liu, Rebecca Kee, Katharine Batt
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert review of pharmacoeconomics & outcomes research (2022)
Katharine Batt, Bob G Schultz, Jorge Caicedo, Christopher S Hollenbeak, Neha Agrawal, Sagnik Chatterjee, Michael Bullano
A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab. Current medical research and opinion 38 (10) (2022)